Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial

G. Raghu, B. van den Blink, MJ. Hamblin, AW. Brown, JA. Golden, LA. Ho, MS. Wijsenbeek, M. Vasakova, A. Pesci, DE. Antin-Ozerkis, KC. Meyer, M. Kreuter, H. Santin-Janin, GJ. Mulder, B. Bartholmai, R. Gupta, L. Richeldi,

. 2018 ; 319 (22) : 2299-2307.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze II, srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033057
E-zdroje Online Plný text

NLK Open Access Digital Library od 1998-01-01 do Před 6 měsíci
Medline Complete (EBSCOhost) od 1998-01-07 do Před 1 měsícem

Importance: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with poor prognosis. Approved therapies do not halt disease progression. Objective: To determine the effect of recombinant human pentraxin 2 vs placebo on change from baseline to week 28 in mean forced vital capacity (FVC) percentage of predicted value. Design, Setting, and Participants: Phase 2, randomized, double-blind, placebo-controlled trial conducted at 18 sites in 7 countries of eligible patients with IPF (N = 117; aged 40-80 years; FVC ≥50% and ≤90% predicted; ratio of forced expiratory volume in the first second/FVC >0.70; diffusing capacity for carbon monoxide [Dlco] ≥25% and ≤90% predicted; and distance of ≥150 m on the 6-minute walk test). Study period was August 2015-May 2017. Interventions: Patients were randomized to receive either recombinant human pentraxin 2 (10 mg/kg intravenous every 4 weeks, n = 77) or placebo (n = 39) for 24 weeks, and stratified by concurrent IPF treatment status. Main Outcomes and Measures: The primary end point was the least-squares mean change in FVC percentage of predicted value from baseline to week 28 (minimal clinically important difference, decline of 2%-6%). Secondary end points included mean change in lung volumes (total, normal, and interstitial lung abnormalities) on high-resolution computed tomography (HRCT) and 6-minute walk distance (minimal clinically important difference, 24-45 m). Results: Of 117 randomized patients, 116 received at least 1 dose of study drug (mean age, 68.6 years; 81.0% men; mean time since IPF diagnosis, 3.8 years), and 111 (95.7%) completed the study. The least-squares mean change in FVC percentage of predicted value from baseline to week 28 in patients treated with recombinant human pentraxin 2 was -2.5 vs -4.8 for those in the placebo group (difference, +2.3 [90% CI, 1.1 to 3.5]; P = .001). No significant treatment differences were observed in total lung volume (difference, 93.5 mL [90% CI, -27.7 to 214.7]), quantitative parenchymal features on HRCT (normal lung volume difference, -1.2% [90% CI, -4.4 to 1.9]; interstitial lung abnormalities difference, 1.1% [90% CI, -2.2 to 4.3]), or measurement of Dlco (difference, -0.4 [90% CI, -2.6 to 1.7]). The change in 6-minute walk distance was -0.5 m for patients treated with recombinant human pentraxin 2 vs -31.8 m for those in the placebo group (difference, +31.3 m [90% CI, 17.4 to 45.1]; P < .001). The most common adverse events in the recombinant human pentraxin 2 vs placebo group were cough (18% vs 5%), fatigue (17% vs 10%), and nasopharyngitis (16% vs 23%). Conclusions and Relevance: In this preliminary study, recombinant human pentraxin 2 vs placebo resulted in a slower decline in lung function over 28 weeks for patients with idiopathic pulmonary fibrosis. Further research should more fully assess efficacy and safety. Trial Registration: clinicaltrials.gov Identifier: NCT02550873.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033057
003      
CZ-PrNML
005      
20181026120059.0
007      
ta
008      
181008s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1001/jama.2018.6129 $2 doi
035    __
$a (PubMed)29800034
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Raghu, Ganesh $u University of Washington, Seattle.
245    10
$a Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial / $c G. Raghu, B. van den Blink, MJ. Hamblin, AW. Brown, JA. Golden, LA. Ho, MS. Wijsenbeek, M. Vasakova, A. Pesci, DE. Antin-Ozerkis, KC. Meyer, M. Kreuter, H. Santin-Janin, GJ. Mulder, B. Bartholmai, R. Gupta, L. Richeldi,
520    9_
$a Importance: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with poor prognosis. Approved therapies do not halt disease progression. Objective: To determine the effect of recombinant human pentraxin 2 vs placebo on change from baseline to week 28 in mean forced vital capacity (FVC) percentage of predicted value. Design, Setting, and Participants: Phase 2, randomized, double-blind, placebo-controlled trial conducted at 18 sites in 7 countries of eligible patients with IPF (N = 117; aged 40-80 years; FVC ≥50% and ≤90% predicted; ratio of forced expiratory volume in the first second/FVC >0.70; diffusing capacity for carbon monoxide [Dlco] ≥25% and ≤90% predicted; and distance of ≥150 m on the 6-minute walk test). Study period was August 2015-May 2017. Interventions: Patients were randomized to receive either recombinant human pentraxin 2 (10 mg/kg intravenous every 4 weeks, n = 77) or placebo (n = 39) for 24 weeks, and stratified by concurrent IPF treatment status. Main Outcomes and Measures: The primary end point was the least-squares mean change in FVC percentage of predicted value from baseline to week 28 (minimal clinically important difference, decline of 2%-6%). Secondary end points included mean change in lung volumes (total, normal, and interstitial lung abnormalities) on high-resolution computed tomography (HRCT) and 6-minute walk distance (minimal clinically important difference, 24-45 m). Results: Of 117 randomized patients, 116 received at least 1 dose of study drug (mean age, 68.6 years; 81.0% men; mean time since IPF diagnosis, 3.8 years), and 111 (95.7%) completed the study. The least-squares mean change in FVC percentage of predicted value from baseline to week 28 in patients treated with recombinant human pentraxin 2 was -2.5 vs -4.8 for those in the placebo group (difference, +2.3 [90% CI, 1.1 to 3.5]; P = .001). No significant treatment differences were observed in total lung volume (difference, 93.5 mL [90% CI, -27.7 to 214.7]), quantitative parenchymal features on HRCT (normal lung volume difference, -1.2% [90% CI, -4.4 to 1.9]; interstitial lung abnormalities difference, 1.1% [90% CI, -2.2 to 4.3]), or measurement of Dlco (difference, -0.4 [90% CI, -2.6 to 1.7]). The change in 6-minute walk distance was -0.5 m for patients treated with recombinant human pentraxin 2 vs -31.8 m for those in the placebo group (difference, +31.3 m [90% CI, 17.4 to 45.1]; P < .001). The most common adverse events in the recombinant human pentraxin 2 vs placebo group were cough (18% vs 5%), fatigue (17% vs 10%), and nasopharyngitis (16% vs 23%). Conclusions and Relevance: In this preliminary study, recombinant human pentraxin 2 vs placebo resulted in a slower decline in lung function over 28 weeks for patients with idiopathic pulmonary fibrosis. Further research should more fully assess efficacy and safety. Trial Registration: clinicaltrials.gov Identifier: NCT02550873.
650    _2
$a senioři $7 D000368
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a homeodoménové proteiny $x škodlivé účinky $x farmakologie $x terapeutické užití $7 D018398
650    _2
$a lidé $7 D006801
650    _2
$a idiopatická plicní fibróza $x farmakoterapie $x patofyziologie $7 D054990
650    _2
$a metoda nejmenších čtverců $7 D016018
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a rekombinantní proteiny $x škodlivé účinky $x farmakologie $x terapeutické užití $7 D011994
650    _2
$a sérový amyloidový protein $x škodlivé účinky $x farmakologie $x terapeutické užití $7 D000683
650    _2
$a vitální kapacita $x účinky léků $7 D014797
650    _2
$a test chůzí $7 D000070857
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a van den Blink, Bernt $u Promedior Inc, Lexington, Massachusetts.
700    1_
$a Hamblin, Mark J $u University of Kansas, Kansas City.
700    1_
$a Brown, A Whitney $u Inova Fairfax Hospital, Falls Church, Virginia.
700    1_
$a Golden, Jeffrey A $u University of California, San Francisco.
700    1_
$a Ho, Lawrence A $u University of Washington, Seattle.
700    1_
$a Wijsenbeek, Marlies S $u Department of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.
700    1_
$a Vasakova, Martina $u First Medical Faculty Charles University and Thomayer Hospital, Prague, Czech Republic.
700    1_
$a Pesci, Alberto $u University of Milano-Bicocca, Monza, Italy.
700    1_
$a Antin-Ozerkis, Danielle E $u Yale School of Medicine, New Haven, Connecticut.
700    1_
$a Meyer, Keith C $u University of Wisconsin, Madison.
700    1_
$a Kreuter, Michael $u Center for Rare and Interstitial Lung Diseases, Thoraxklinik, University of Heidelberg, Heidelberg, Germany.
700    1_
$a Santin-Janin, Hugues $u Venn Life Sciences, Paris, France.
700    1_
$a Mulder, Geert-Jan $u Promedior Inc, Lexington, Massachusetts.
700    1_
$a Bartholmai, Brian $u Mayo Clinic, Rochester, Minnesota.
700    1_
$a Gupta, Renu $u Promedior Inc, Lexington, Massachusetts.
700    1_
$a Richeldi, Luca $u Unità Operativa Complessa di Pneumologia, IRCCS Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy.
773    0_
$w MED00002973 $t JAMA $x 1538-3598 $g Roč. 319, č. 22 (2018), s. 2299-2307
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29800034 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181026120610 $b ABA008
999    __
$a ok $b bmc $g 1339356 $s 1030051
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 319 $c 22 $d 2299-2307 $i 1538-3598 $m JAMA (Chicago, Ill.) $n JAMA $x MED00002973
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...